Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.00% | 8.06% | 6.59% | 5.67% | 6.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.00% | 8.06% | 6.59% | 5.67% | 6.37% |
| Cost of Revenue | 7.67% | 6.89% | 5.81% | 3.57% | 5.55% |
| Gross Profit | 11.83% | 8.98% | 7.20% | 7.35% | 7.03% |
| SG&A Expenses | 26.06% | 17.04% | 10.36% | 5.22% | 5.18% |
| Depreciation & Amortization | 35.83% | 8.28% | -7.78% | -10.44% | -8.92% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.40% | 10.45% | 6.44% | 3.35% | 4.95% |
| Operating Income | -12.70% | -2.07% | 7.24% | 16.33% | 12.78% |
| Income Before Tax | -19.37% | -4.90% | 10.63% | 20.72% | 20.06% |
| Income Tax Expenses | 131.87% | 134.30% | 130.27% | 130.40% | -677.55% |
| Earnings from Continuing Operations | -66.37% | -61.19% | -53.52% | -51.32% | 142.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.37% | -61.19% | -53.52% | -51.32% | 142.36% |
| EBIT | -12.70% | -2.07% | 7.24% | 16.33% | 12.78% |
| EBITDA | -2.50% | 1.19% | 5.10% | 10.47% | 8.06% |
| EPS Basic | -66.49% | -61.34% | -53.68% | -51.46% | 142.33% |
| Normalized Basic EPS | -19.66% | -5.53% | 7.58% | 17.21% | 15.43% |
| EPS Diluted | -66.48% | -61.34% | -53.75% | -51.43% | 142.48% |
| Normalized Diluted EPS | -19.51% | -5.41% | 7.65% | 17.25% | 15.46% |
| Average Basic Shares Outstanding | -0.09% | 0.06% | 0.11% | 0.04% | 0.00% |
| Average Diluted Shares Outstanding | -0.26% | -0.07% | 0.03% | 0.00% | -0.04% |
| Dividend Per Share | 6.78% | 6.90% | 7.02% | 7.14% | 7.27% |
| Payout Ratio | 2.18% | 1.76% | 1.31% | 1.20% | -0.56% |